Velamoor Expands Role to President and COO; Hammerschmidt to Assume CFO Position Upon Arnold’s Retirement
REMOTE-FIRST COMPANY/IRVINE, Calif.–(BUSINESS WIRE)–#NextGenHealthcare–Entering the new year with a continued commitment to delivering transformative healthcare technology solutions, NextGen Healthcare today announced two key executive promotions that will support the organization’s long-term strategic growth. Effective immediately, Srinivas (Sri) Velamoor has been promoted to president and chief operating officer and James Hammerschmidt has been named as the incoming chief financial officer. David Sides remains chief executive officer.
In his new role, Velamoor will lead product, technology, strategy, M&A and business development, as well as Revenue Cycle and EDI managed services.
Velamoor joined NextGen Healthcare in 2021 as chief growth and strategy officer and executive vice president, bringing more than two decades of experience driving growth and performance at global healthcare, financial services and technology organizations. He served for 10 years as partner and health sector leader for McKinsey & Company’s North America digital and analytics and ‘Leap’ business-building practices. Prior to McKinsey, Velamoor was a partner at both PricewaterhouseCoopers and Diamond Management & Technology Consultants and held operating leadership roles in other growth stage companies and start-ups.
After 8 years of dedicated service, NextGen Healthcare’s chief financial officer Jamie Arnold has announced plans to retire on March 31, 2024. An industry veteran with more than three decades of finance and software technology experience, Arnold was recognized in 2022 with a Lifetime Achievement Award by the Orange County Business Journal. Arnold has been integral to NextGen Healthcare’s financial success and leaves behind a legacy of fiscal prudence and strategic vision.
James Hammerschmidt has been named Arnold’s successor as the incoming chief financial officer. Hammerschmidt joined NextGen Healthcare in 2017 and today serves as senior vice president of finance and investor relations. He has been a prominent member of the leadership team responsible for financial planning and analysis, corporate finance, business intelligence, and investor relations, and played a key role in the company’s acquisition by Thoma Bravo.
“I want to extend my deepest gratitude to Jamie Arnold for his years of exemplary service. He has been a cornerstone of our success, and his leadership and partnership will be greatly missed,” said David Sides, chief executive officer and president, NextGen Healthcare. “In the spirit of continued growth and excellence, I am delighted to recognize Sri Velamoor and James Hammerschmidt as they expand their focus in their respective new roles. 2024 will be a bright year for NextGen Healthcare as we continue working together to enable better healthcare outcomes for all.”
About NextGen Healthcare, Inc.
NextGen Healthcare, Inc. is a leading provider of innovative healthcare technology and data solutions. We are reimagining ambulatory healthcare with award-winning EHR, practice management and surround solutions that enable providers to deliver whole-person health and value-based care. Our highly integrated, intelligent, and interoperable solutions increase clinical quality and productivity, enrich the patient experience and drive superior financial performance. We are on a relentless quest to achieve better healthcare outcomes for all. Learn more at nextgen.com, and follow us on Facebook, X, LinkedIn, YouTube, and Instagram.
Contacts
Media Contact
Anjali Bright
(731) 234-6422
Abright@nextgen.com
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN…
BOUCHERVILLE, Québec, June 28, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL, LSL.DB)…
SALINAS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL;…
MINNEAPOLIS, MN, US, June 28, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTC: PETV, PETVW),…
BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or…
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a…